Keep it, share it, but don’t sell it: what Massachusetts’ Question 8 would actually do

Massachusetts votes next month on whether to close its licensed adult-use cannabis market, and the ballot text is stranger than the slogans suggest. Also this week: two US hemp deadlines, the oversight gap in England’s private prescribing market and a revealing DEA decision.

Question 8: possession without supply

On 3 November, Massachusetts voters decide Question 8, usually described as a repeal of recreational cannabis. That is half right. The measure would leave adults free to carry cannabis while closing almost every lawful, non-medical way of obtaining it.

What the text changes

From 1 January 2028, the law would repeal Chapter 94G, the adult-use framework that grew out of the 2016 legalisation vote, and the chapter that taxes retail sales. According to the state’s fiscal statement, that tax raised roughly $280 million for the state and $50 million for local governments in fiscal 2025. The Cannabis Control Commission would oversee only the medical programme.

Possession would not be recriminalised. Adults aged 21 and over could hold up to one ounce (no more than five grams of concentrate) without penalty, and give up to an ounce to another adult if the transfer is “without remuneration” and “not advertised or promoted to the public”. Holding one to two ounces would bring a $100 civil fine, reversing the two-ounce limit introduced this April.

Home growing is where coverage has often gone wrong. Adults may now grow six plants for personal use, but that permission sits in Chapter 94G, which Question 8 repeals in full. The new possession rules do not mention cultivation. The state’s separate offence for anyone who “cultivates” a Class D substance, a category that includes marijuana, is left untouched. The only home growing the text clearly preserves is the hardship route for registered medical patients. On our reading, adult home growing would lose its legal protection. Whether that would expose people growing a few plants to prosecution is a question the measure does not answer, and one on which lawyers may differ.

The paradox

An adult could lawfully possess an ounce, or accept one as a gift. Outside the medical programme, though, there would be no lawful way to buy cannabis in Massachusetts and, it appears, no protected way to grow it. Neighbouring states’ shops are not a lawful supply route either: carrying cannabis across a state line remains a federal offence.

Washington, DC, offers a partial precedent. Its 2014 Initiative 71 allowed possession, home growing and gifts while Congress blocked licensed sales, producing what DCist described as a “gifting economy” of $50 stickers sold with “free” cannabis. Question 8’s ban on advertised transfers reads as an attempt to prevent that.

The key distinction is between removing commercial sales and replacing them. A 2023 RAND Europe review for the Swiss government describes the main non-commercial routes that jurisdictions have tried: home cultivation, cannabis social clubs and government-controlled sales, as in parts of Canada and Uruguay. Germany’s 2024 law, for example, bars shops but allows adults to grow three plants at home and join non-profit cultivation associations. RAND notes that rigorous evaluations of these models remain rare, but each defines a lawful source. Question 8 removes the commercial channel without designating an alternative.

The case on each side

The Yes campaign, largely funded by the national group Smart Approaches to Marijuana Action, says the measure keeps personal and medical use legal while ending commercial stores. Its official argument cites fatal crashes, workplace costs and the mental-health risks of high-potency products for young adults. The position is coherent: the problem is commerce, not consumption.

The No campaign argues that a decade of regulation has delivered tested, labelled products sold only to adults. It warns that repeal would push buyers to unregulated sellers, cost jobs and revenue, and revive enforcement that historically fell hardest on communities of colour. That points to the strongest analytical objection: much of the regulatory toolkit, from testing and labelling to potency limits and ID checks, attaches to licensed sale. A possession-only regime keeps users out of court but has little purchase on what they consume. How far demand would shift to illicit sellers is uncertain.

The state of the race

A University of New Hampshire poll of 564 likely voters, conducted from 17 to 21 September, found 71% planning to vote no, 24% yes and 5% unsure. A MassINC Polling Group survey for CommonWealth Beacon of 800 likely voters, conducted from 14 to 22 September, put opposition at 61%, support at 27% and undecided at 11%.

Whatever the result, the measure is a useful test. Most US states that legalised cannabis paired use and supply from the start. Question 8 tries to separate them, and shows the difficulty of doing so without deciding where the cannabis comes from. The licensed market would close; the demand for supply would not.

Hemp restrictions arrive in two stages

The federal redefinition of hemp, enacted in November 2025, now takes effect in two steps. From 12 November, products containing cannabinoids “not capable of being naturally produced” by the cannabis plant fall outside the legal definition of hemp. According to the Congressional Research Service, such products are then “to be classified as marijuana under the CSA”. The rest of the new definition is delayed until 11 December by September’s stopgap funding law. That includes a cap of 0.4 milligrams of THC per container, widely expected to exclude most intoxicating hemp products as currently sold.

One piece of machinery is missing. Congress gave the FDA 90 days to publish lists of naturally occurring and THC-like cannabinoids, and to explain what counts as a “container”. That deadline passed in February. As of 28 September the lists had not appeared, according to the CRS, and we found nothing in the Federal Register by 12 October.

The gap should not be overstated: the exclusions are in the statute and do not depend on the lists to take legal effect. But without them, the line will be argued product by product.

England’s private cannabis market is outgrowing its oversight

A Press Association analysis of NHS Business Services Authority data, published on 7 October, counted 1,967,268 items of unlicensed cannabis products on private prescriptions between June 2025 and May 2026, three-quarters of them flower. Separately, the Care Quality Commission’s annual controlled drugs report, published in July, recorded 833,525 items in the financial year to March 2025, up 134% on the previous year. The two series cover different periods and are not directly comparable. Both count prescription items, not patients.

The more revealing material in the CQC report concerns who prescribes and who can see it. In 2024, pharmacist prescribers, who may prescribe these products under a specialist’s direction, wrote 441,409 items, against 209,644 written by doctors. The CQC notes that the 2018 change was intended mainly for a small number of conditions. The regulator says most prescribing is concentrated among “a relatively small number of doctors and pharmacists”. It also says it is “unable to view prescribing data at provider level due to how the private prescribing system works in practice”. NHS England has advised that there is no power to refuse a private prescriber number to an appropriately registered professional, or to withdraw one once issued.

Responsibility is spread thinly: the CQC registers clinics, professional regulators oversee individuals and prescribing data sits with the NHS Business Services Authority. Meanwhile, ministers said in a written answer on 9 September that fewer than five patients nationally receive unlicensed cannabis products through NHS prescriptions. England’s Patient Safety Commissioner, Professor Henrietta Hughes, said this week that prescribing growth “has outpaced the systems needed to ensure patient safety”.

The official review of the 2018 framework, by the Advisory Council on the Misuse of Drugs, was due by summer 2026. In a letter to the policing minister published on 21 September, its chair said reports were now expected “by the end of the year”. Its most important task may be less about clinical evidence than about accountability: who answers for a market that has grown faster than anyone’s ability to see it.

DEA calls an adult-use business “diversion”, but decides less than it seems

On 7 October, the Drug Enforcement Administration published its refusal of MedPharm Research, a Denver company that applied in 2016 to register as a bulk manufacturer of marijuana. DEA found that its parent and a sister company, which share a chief executive, had supplied Colorado’s recreational market for at least a decade without federal registration, and treated that as diversion weighing against the public interest.

The decision is narrower than its language. MedPharm did not request a hearing, so the allegations were deemed admitted, and the application was assessed under the old Schedule I rules. DEA noted that the company may still apply under the new framework, created by April’s order, which moved state-licensed medical marijuana into Schedule III but still lets DEA refuse registrations inconsistent with the public interest.

That is the open question for operators serving both medical and adult-use customers, which The Cannigma examined in June. According to law firm Foley Hoag, DEA’s new registration forms ask applicants whether they will handle recreational marijuana. MedPharm does not show what DEA will do with the answers, only the language it is prepared to use.

Was this useful for you? Yes 0 No 0

Why not?